Bolt Biotherapeutics, Inc. (BOLT): Shareholders' Equity
$26.50M
As of 2025-12-31
$12.64M
As of 2026-06-30
-46.3%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $26.50M | -53.7% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $57.20M | -49.3% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $112.74M | -34.3% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $171.51M | -31.4% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $250.12M | n/m | 2023-03-29, Balance as of period end |
| 2020-12-31 | -$104.95M | n/a | 2022-03-30, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $26.50M | -53.7% |
| Adagene Inc. (ADAG) | 2025-12-31 | $35.35M | -30.0% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $103.08M | -33.7% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $581.76M | -22.9% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $43.03M | +8.7% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $130.66M | +91.5% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $4.53B | -3.4% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $136.31M | +159.7% |
| Immunome Inc. (IMNM) | 2025-12-31 | $634.34M | +250.1% |
Compare BOLT, ADAG, ACRS, XENE side by side · Screen every company in Pharmaceutical Preparations ↗